Taken together, our results suggest that prior patient exposure to Pseudomonas or immunity directed against its exotoxin does not diminish the therapeutic potential of IL13-PE in the treatment of pulmonary fibrosis. The gene discussed is IL13; the disease is pulmonary fibrosis.